Moolec Science (MLECW) Return on Capital Employed (2023 - 2024)
Moolec Science (MLECW) posted Return on Capital Employed of 35.84% for Q4 2024, down 1853.43% sequentially from 1.83% in Q3 2024, and up 3406.0% YoY from 1.02% in Q1 2024.
Moolec Science (MLECW) Return on Capital Employed (2023 - 2024) Analysis & Trends
Moolec Science has reported Return on Capital Employed for 2 years, with the latest figure at 35.84% in Q4 2024.
- Quarterly Return on Capital Employed rose 3406.0% year-over-year to 35.84% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 35.84% (up 3406.0% YoY) and the FY2024 annual result came in at 15.19%, down 5846.0% from the prior year.
- Return on Capital Employed declined to 35.84% in Q4 2024 per MLECW's latest filing, from 1.83% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 45.04% in Q2 2023 and troughed at 76.25% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -35.84% |
| Sep 30, 2024 | -1.83% |
| Jun 30, 2024 | -14.95% |
| Mar 31, 2024 | -64.41% |
| Dec 31, 2023 | -69.90% |
| Sep 30, 2023 | -76.25% |
| Jun 30, 2023 | 45.04% |
| Mar 31, 2023 | -31.95% |